We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App





Fluxergy Collaborates with Mass General Brigham to Evaluate One-Hour COVID-19 Diagnostic Test

By HospiMedica International staff writers
Posted on 03 Jul 2020
Print article
Image: The Fluxergy diagnostic testing system (Photo courtesy of Fluxergy)
Image: The Fluxergy diagnostic testing system (Photo courtesy of Fluxergy)
Fluxergy (Irvine, CA, USA) will work with Mass General Brigham (MGB Boston, MA, USA) to further evaluate the company’s innovative Research Use Only (RUO) COVID-19 testing platform, designed to deliver accurate PCR test results in under one hour.

Fluxergy has filed a request for an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). If granted, the EUA would permit medical sites with CLIA-certified high complexity laboratories, such as MGB, to use the Fluxergy system as a COVID-19 diagnostic tool in accordance with the FDA's authorization. Subject to confirming the performance of the Fluxergy system, and the potential receipt by Fluxergy of the EUA, MGB may utilize the new platform within its healthcare system. MGB also has plans to publish its findings for review by other medical institutions.

Fluxergy is also working to develop additional validation data that may support a possible future EUA request to use its COVID-19 testing system at the point-of-care, such as at physician offices, urgent care centers, and outreach clinics. Fluxergy has also begun initial work developing a first-of-its-kind multimodal test that may be able to perform a combined PCR and immunoassay (antibody) COVID-19 analysis using a single Fluxergy test card.

"MGB is committed to working collaboratively with innovators in the medical field like Fluxergy to help assess new technologies that may enable our hospitals and other medical institutions to more quickly and accurately identify patients with COVID-19, and keep medical staff safely on the job," said Lauren Ritterhouse, MD, PhD, Associate Director for the Center for Integrated Diagnostics in the Department of Pathology at Massachusetts General Hospital, and Assistant Professor at Harvard Medical School.

"Fluxergy is proud to work with Mass General Brigham, one of the nation's most respected healthcare systems, to assist in evaluating the efficacy of the Fluxergy COVID-19 PCR test," said Dr. Ali Tinazli, Fluxergy's Chief Commercialization Officer.

Related Links:
Fluxergy
Mass General Brigham


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
Double Door Pharmacy Refrigerator
iPR256-GX
New
Mattress Replacement System
Apollo Infant Dynamic

Print article

Channels

Critical Care

view channel
Image: The digital twin of the heart helps to improve the diagnosis and treatment of cardiac arrhythmias (Photo courtesy of UPV)

Digital Heart Twin Improves Diagnosis and Treatment of Cardiac Arrhythmias

Millions of individuals around the globe suffer from cardiac arrhythmias. Traditionally, electrocardiography (ECG) has been used to detect premature ventricular contractions (PVCs), one of the most common... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.